Clinical characterization of Lassa fever: A systematic review of clinical reports and research to inform clinical trial design.

ABSTRACT:

Background

Research is urgently needed to reduce the morbidity and mortality of Lassa fever (LF), including clinical trials to test new therapies and to verify the efficacy and safety of the only current treatment recommendation, ribavirin, which has a weak clinical evidence base. To help establish a basis for the development of an adaptable, standardised clinical trial methodology, we conducted a systematic review to identify the clinical characteristics and outcomes of LF and describe how LF has historically been defined and assessed in the scientific literature.

Methodology

Primary clinical studies and reports of patients with suspected and confirmed diagnosis of LF published in the peer-reviewed literature before 15 April 2021 were included. Publications were selected fo

SUBMITTER: Merson L 

PROVIDER: S-EPMC8486098 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature